Literature DB >> 26845349

Cannabidiol, neuroprotection and neuropsychiatric disorders.

Alline C Campos1, Manoela V Fogaça2, Andreza B Sonego2, Francisco S Guimarães2.   

Abstract

Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders. CBD attenuates brain damage associated with neurodegenerative and/or ischemic conditions. It also has positive effects on attenuating psychotic-, anxiety- and depressive-like behaviors. Moreover, CBD affects synaptic plasticity and facilitates neurogenesis. The mechanisms of these effects are still not entirely clear but seem to involve multiple pharmacological targets. In the present review, we summarized the main biochemical and molecular mechanisms that have been associated with the therapeutic effects of CBD, focusing on their relevance to brain function, neuroprotection and neuropsychiatric disorders.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  5HT1A receptor; Cannabidiol; Endocannabinoids; Neuropsychiatric disorders; Oxidative stress; PPAR-γ receptor

Mesh:

Substances:

Year:  2016        PMID: 26845349     DOI: 10.1016/j.phrs.2016.01.033

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  84 in total

1.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

2.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

Review 3.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

Review 4.  Marijuana Use in Pregnancy and While Breastfeeding.

Authors:  Torri D Metz; Laura M Borgelt
Journal:  Obstet Gynecol       Date:  2018-11       Impact factor: 7.661

5.  Involvement of Hippocampal D1-Like Dopamine Receptors in the Inhibitory Effect of Cannabidiol on Acquisition and Expression of Methamphetamine-Induced Conditioned Place Preference.

Authors:  Kiana Nouri; Mahsa Anooshe; Saeideh Karimi-Haghighi; Zahra Mousavi; Abbas Haghparast
Journal:  Neurochem Res       Date:  2021-05-15       Impact factor: 3.996

Review 6.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

7.  Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.

Authors:  Jasmine Turna; Sabrina K Syan; Benicio N Frey; Brian Rush; Mary Jean Costello; Mark Weiss; James MacKillop
Journal:  Alcohol Clin Exp Res       Date:  2019-02-19       Impact factor: 3.455

Review 8.  Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Authors:  Roger Hudson; Walter Rushlow; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

9.  Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.

Authors:  Alyssa M Myers; Patrick B Siegele; Jeffrey D Foss; Ronald F Tuma; Sara Jane Ward
Journal:  Br J Pharmacol       Date:  2018-03-01       Impact factor: 8.739

10. 

Authors:  Jairo Vinícius Pinto; Gayatri Saraf; Christian Frysch; Daniel Vigo; Kamyar Keramatian; Trisha Chakrabarty; Raymond W Lam; Márcia Kauer-Sant'Anna; Lakshmi N Yatham
Journal:  Can J Psychiatry       Date:  2019-12-13       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.